Abstract Number: 2060 • 2015 ACR/ARHP Annual Meeting
Microscopic Bowel Inflammation in Spondyloarthritis As a Baseline Predictor of Anti-TNF Response
· Background/Purpose: Microscopic bowel inflammation without associated gastro-intestinal symptoms is present in up to 50% of spondyloarthritis (SpA) patients. Two types of inflammation are distinguished based…Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…Abstract Number: 1313 • 2015 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry
Background/Purpose: Rheumatoid arthritis (RA) is characterised by progressive joint destruction and loss of periarticular bone mass. Thus hand bone loss (HBL) has been proposed as…Abstract Number: 2105 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Cost Effectiveness in Patients on Reduced Dose Anti-TNF: Results of a 4 Year Prospective Observational Study
Background/Purpose: Anti-TNF-α drugs are effective treatments for patients with inflammatory arthritis (IA). They are however expensive and their use carries a significant cost burden to…Abstract Number: 2862 • 2015 ACR/ARHP Annual Meeting
Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review
Background/Purpose: Anti-TNF therapy is successful for achieving low disease activity (LDA) or clinical remission in patients with axial spondyloarhritis (axSpA). Nevertheless, this therapy has not…Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…Abstract Number: 1331 • 2015 ACR/ARHP Annual Meeting
Change in MRI in Patients with Spondyloarthritis Treated with Anti-TNF Agents : Systematic Review of the Literature
Background/Purpose: The follow-up of axial spondyloarthritis (SpA) remains difficult in clinical practice, mainly based on patient-reported outcomes, whereas objective parameters in disease monitoring are often…Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…Abstract Number: 2867 • 2015 ACR/ARHP Annual Meeting
Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study
Background/Purpose: Progression of psoriatic arthritis (PsA) can lead to irreversible joint damage and functional impairment. TNF inhibitors (TNFi’s) have been shown to improve signs and…Abstract Number: 616 • 2015 ACR/ARHP Annual Meeting
Risk Factors for the Exacerbation of Interstitial Lung Disease (ILD) after Administration of Biologic Dmards in RA Patients with Pre-Existing ILD
Background/Purpose: Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of death…Abstract Number: 1351 • 2015 ACR/ARHP Annual Meeting
Long-Term Efficacy of Latent Tuberculosis Infection Screening in Juvenile Idiopathic Arthritis Patients Prior to Anti-TNF Treatment in an Endemic Area
Background/Purpose: We have demonstrated previously that latent tuberculosis infection (LTBI) screening is effective in adult rheumatoid arthritis (RA) patients prior to anti-TNF treatment. One study…Abstract Number: 2149 • 2015 ACR/ARHP Annual Meeting
Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial
Background/Purpose: Tumour Necrosis Factor alpha inhibitors (TNFi) have proven to be effective in the treatment of with spondyloarthropaties. There is rationale to support that in…Abstract Number: 2869 • 2015 ACR/ARHP Annual Meeting
Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis
Background/Purpose: : Previous controlled clinical trials have shown that concurrent methotrexate (MTX) therapy may enhance the efficacy of anti-TNF agents. However, real-world data on the…Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 29
- Next Page »